Genmab A/S has added two new people to its executive committee as it expands its portfolio of antibody medicines for cancer. At the same time, Anthony Mancini, the chief operating officer, has decided to leave the company to pursue other opportunities. The new committee members are Rayne Waller and Brad Bailey who have been named respectively chief technology officer and chief commercial officer. They will both report to the chief executive Jan van de Winkel. Mr Waller was most recently chief operating officer at Capsida Biotherapeutics Inc, a gene therapy platform company. Prior to this, he worked at Amgen Inc in manufacturing and supply chain management. Mr Bailey joined Genmab in 2020 as general manager for the US. He has been promoted to chief commercial officer to oversee the commercialisation of the company’s newest products.
Genmab announced the appointments on 16 August 2024.
Copyright 2024 Evernow Publishing Ltd